Literature DB >> 34722471

Prognostic and Clinicopathologic Significance of Discoidin Domain Receptors in Different Human Malignancies: A Meta-Analysis.

Gordon A Ferns1, Sheida Shabanian2, Milad Shahini Shams Abadi3, Ahmadshah Farhat4, Mohammad-Hassan Arjmand5,6.   

Abstract

BACKGROUND: Discoidin domain receptors (DDRs) belong to the receptor tyrosine kinases family and are activated by different types of collagens, which play roles in various physiological processes. An abnormal expression of DDRs is reported in different types of cancers. Despite many reports about the association and roles of high DDR expression levels in cancers, the prognostic values of DDRs are still unclear. This meta-analysis was performed to evaluate the prognostic effect of DDRs in different tissue cancers.
METHOD: A literature search was performed in several related databases to find eligible English articles. Based on our research, 20 appropriate studies with 2,602 patients were selected till October 5, 2020. The pooled hazard ratio (HR) with a corresponding 95% confidence interval (CI) was computed to evaluate the strength of correlation between DDRs and survival of cancer patients. RESULT: Pooling results showed that a high DDR expression was significantly associated with poorer overall survival (OS) (HR = 1.304, 95% CI 1.007-1.69, p = 0.04). Subgroup analysis based on cancer type revealed a significant link between a high DDR expression level and poor OS both in gastrointestinal (pooled HR = 1.78, 95% CI 1.214-2.624, p = 0.003) and urological cancers (pooled HR = 1.42, 95% CI 1.062-1.82, p = 0.018).
CONCLUSION: Our meta-analysis results suggest that high DDRs expression has the potential to be used as a biomarker of poor prognosis in cancers.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  Cancer prognosis; Discoidin domain receptors; Meta-analysis

Year:  2021        PMID: 34722471      PMCID: PMC8546456          DOI: 10.1159/000517503

Source DB:  PubMed          Journal:  Gastrointest Tumors        ISSN: 2296-3774


  41 in total

1.  The discoidin domain receptor DDR2 is a receptor for type X collagen.

Authors:  Birgit Leitinger; Alvin P L Kwan
Journal:  Matrix Biol       Date:  2006-05-26       Impact factor: 11.583

2.  Tyrosine kinase discoidin domain receptors DDR1 and DDR2 are coordinately deregulated in triple-negative breast cancer.

Authors:  Kathy A Toy; Rajeshwari R Valiathan; Fernando Núñez; Kelley M Kidwell; Maria E Gonzalez; Rafael Fridman; Celina G Kleer
Journal:  Breast Cancer Res Treat       Date:  2015-02-10       Impact factor: 4.872

3.  Switching in discoid domain receptor expressions in SLUG-induced epithelial-mesenchymal transition.

Authors:  Michiko Maeyama; Hironori Koga; Karuppaiyah Selvendiran; Chikatoshi Yanagimoto; Shinichiro Hanada; Eitaro Taniguchi; Takumi Kawaguchi; Masaru Harada; Takato Ueno; Michio Sata
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

4.  Phosphorylation of DARPP-32 regulates breast cancer cell migration downstream of the receptor tyrosine kinase DDR1.

Authors:  Christian Hansen; Paul Greengard; Angus C Nairn; Tommy Andersson; Wolfgang F Vogel
Journal:  Exp Cell Res       Date:  2006-09-09       Impact factor: 3.905

5.  Discoidin domain receptor 2 facilitates prostate cancer bone metastasis via regulating parathyroid hormone-related protein.

Authors:  Zhang Yan; Su Jin; Zhang Wei; Hou Huilian; Yin Zhanhai; Teng Yue; Li Juan; Li Jing; Yao Libo; Li Xu
Journal:  Biochim Biophys Acta       Date:  2014-04-27

6.  DDR2 and IFITM1 Are Prognostic Markers in Gallbladder Squamous Cell/Adenosquamous Carcinomas and Adenocarcinomas.

Authors:  Daiqiang Li; Zhulin Yang; Ziru Liu; Qiong Zou; Yuan Yuan
Journal:  Pathol Oncol Res       Date:  2017-10-17       Impact factor: 3.201

7.  Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.

Authors:  Peter S Hammerman; Martin L Sos; Alex H Ramos; Chunxiao Xu; Amit Dutt; Wenjun Zhou; Lear E Brace; Brittany A Woods; Wenchu Lin; Jianming Zhang; Xianming Deng; Sang Min Lim; Stefanie Heynck; Martin Peifer; Jeffrey R Simard; Michael S Lawrence; Robert C Onofrio; Helga B Salvesen; Danila Seidel; Thomas Zander; Johannes M Heuckmann; Alex Soltermann; Holger Moch; Mirjam Koker; Frauke Leenders; Franziska Gabler; Silvia Querings; Sascha Ansén; Elisabeth Brambilla; Christian Brambilla; Philippe Lorimier; Odd Terje Brustugun; Aslaug Helland; Iver Petersen; Joachim H Clement; Harry Groen; Wim Timens; Hannie Sietsma; Erich Stoelben; Jürgen Wolf; David G Beer; Ming Sound Tsao; Megan Hanna; Charles Hatton; Michael J Eck; Pasi A Janne; Bruce E Johnson; Wendy Winckler; Heidi Greulich; Adam J Bass; Jeonghee Cho; Daniel Rauh; Nathanael S Gray; Kwok-Kin Wong; Eric B Haura; Roman K Thomas; Matthew Meyerson
Journal:  Cancer Discov       Date:  2011-06       Impact factor: 39.397

8.  Cancer Statistics for Hispanics/Latinos, 2018.

Authors:  Kimberly D Miller; Ann Goding Sauer; Ana P Ortiz; Stacey A Fedewa; Paulo S Pinheiro; Guillermo Tortolero-Luna; Dinorah Martinez-Tyson; Ahmedin Jemal; Rebecca L Siegel
Journal:  CA Cancer J Clin       Date:  2018-10-04       Impact factor: 508.702

9.  Analysis of gene expression in cyclooxygenase-2-overexpressed human osteosarcoma cell lines.

Authors:  Jeong A Han; Ji-Yeon Kim; Jong-Il Kim
Journal:  Genomics Inform       Date:  2014-12-31

10.  E2F1 silencing inhibits migration and invasion of osteosarcoma cells via regulating DDR1 expression.

Authors:  Zhaofeng Wang; Xianjie Sun; Yi Bao; Juanfen Mo; Hengchao Du; Jichao Hu; Xingen Zhang
Journal:  Int J Oncol       Date:  2017-10-16       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.